The potential cost-effectiveness of novel cord blood therapies in children with autism spectrum disorder.

A modestly effective intervention designed to improve adaptive behavior in autism can be cost-effective under certain circumstances. Intervention cost and efficacy most affected the cost-effectiveness results and should be targeted to increase economic efficiency.